• Oxford and AstraZeneca test vaccine against Beta variant

  • Vaccine.

    Hope: "At least one dose to everyone by the summer. Today a beautiful day, Italy all white"

  • Vaccines.

    Abrignani: "With two doses protected at 85-90% by Delta"

Share

June 28, 2021 A third dose of Vaxzevria (AstraZeneca) "administered at least 6 months after the second, increased antibody levels six-fold and maintained T cell response. A third dose also resulted in increased neutralizing activity against Alpha variants. Beta and Delta ". This was established by a study, which will be published in the 'Lancet', of the University of Oxford. According to the pre-print results, "both the second and third doses caused fewer adverse reactions than the first".       



The study reveals "reassuring news for countries with lower vaccine supplies, which may be concerned about delays in administering second doses - warns Andrew J. Pollard, lead researcher of the Oxford Vaccine Group - There is an excellent answer. at a second dose, even after 10 months of delay from the first ". The analysis included volunteers aged 18 to 55 who were enrolled in the studies and received a single dose or two doses of AstraZeneca COVID-19 vaccine.     



"Demonstrating that our vaccine generates a robust and long-lasting immune response is important for building confidence in long-term protection," said Mene Pangalos, executive vice president of AstraZeneca's biopharmaceutical research and development.